Caroline Pilot

Lead and deliver complex, multi-stakeholder projects, translating evidence, market insights and clinical input into practical frameworks that support implementation and real-world adoption across healthcare settings. Operate in fast-paced, high-visibility environments requiring strong commercial judgement, prioritisation and execution.

Work closely with clinicians, researchers, consumer organisations and system leaders to ensure outputs are aligned to clinical practice, stakeholder needs and implementation realities. The role combines strategic thinking with a strong focus on delivery, stakeholder alignment and impact.

Key responsibilities

· Lead end-to-end project delivery, from scoping and evidence synthesis through to development of practical, implementation-ready outputs

· Translate complex evidence and stakeholder insight into clear frameworks and recommendations that support uptake and adoption

· Design and facilitate targeted workshops and consultations with clinicians and partners to align perspectives and drive engagement

· Collaborate with communications and stakeholder teams to support dissemination, engagement and application of outputs

· Partner with senior clinical experts and stakeholders to ensure relevance, credibility and real-world applicability

· Integrate lived-experience insights to strengthen relevance and support adoption in practice

Coordinator & Co-Author — Enhanced Primary Care for Healthy Ageing Literature Review (2025)

Led a national evidence review examining models of care, workforce, technology and consumer partnership; developed prioritisation tools to support implementation; delivered findings through stakeholder workshops with general practices and partners including COTA Queensland and CheckUP.

Contributing Author — Getting Australia’s Health on Track 2024

Co-authored a national prevention blueprint, contributing policy actions and supporting communication and dissemination across government, health services and community audiences.

Championed advancing public health, prevention and early-detection initiatives, with a strong focus on improving equitable access to meningococcal vaccination and strengthening preparedness and awareness pathways. The work involved close collaboration with government, clinicians, advocacy organisations and community groups to reduce preventable harm and support prevention and early diagnosis.

The role required sensitive engagement with families affected by severe and life-threatening illness, balancing clinical evidence, public education and lived-experience advocacy to support timely recognition, access and system change.

· Led national disease awareness and education campaigns targeting clinicians, consumers and community stakeholders, increasing awareness and supporting early recognition and vaccine uptake

· Played a key role in establishing Meningococcal Australia, strengthening advocacy and influencing inclusion of meningococcal vaccination within the National Immunisation Program

· Partnered with government stakeholders to progress national tenders and access pathways, supporting broad population access and program delivery

· Coordinated cross-sector engagement across clinicians, regulators and advocacy groups to align messaging, strengthen positioning and support adoption

· Built strong partnerships across clinical, regulatory and distribution networks to ensure effective rollout and delivery of vaccination programs

· Delivered strategic planning and implementation activities aligned to national priorities, supporting sustained program performance and impact

Led market development initiatives to expand access and uptake of influenza vaccination through the introduction of community-based delivery models across Australia. Partnered with clinical, pharmacy and public health stakeholders to establish new service pathways, build capability and support scalable rollout in a regulated environment.

· Co-developed and implemented community pharmacy vaccination pathways, expanding access points and increasing uptake of influenza vaccination

· Partnered with professional bodies and clinical stakeholders to establish practice standards, workforce capability and safe delivery models

· Strengthened distribution and cold chain systems to ensure reliable product availability and consistent service delivery across urban and regional markets

· Built and managed partnerships with wholesalers and frontline providers to support reach, access and sustained utilisation

· Contributed to global product strategy and launch readiness, aligning local execution with broader commercial and market objectives

Coordinated cross-functional and cross-agency stakeholders to enable scalable rollout of new care delivery models

Led the national immunoglobulin portfolio across neurology and oncology, managing a >$500M portfolio (A&P >$2M) through product transition and increased competition. Delivered aligned commercial, sales and stakeholder strategies to maintain market share, strengthen utilisation and support continued growth in a specialist-driven market.

• Maintained market share and stakeholder confidence during competitor entry and supply transition, ensuring continuity of therapy and minimising disruption to utilisation
• Developed and delivered targeted clinician education initiatives that reinforced product positioning, strengthened confidence and supported treatment decision-making
• Expanded specialist engagement across neurology, haematology and oncology networks to increase product utilisation and support sustained adoption
• Designed and implemented an Advocacy and Awareness strategy, improving consistency of access pathways and strengthening stakeholder alignment
• Partnered with patient advocate Michael Klim to integrate lived-experience perspectives into specialist education, enhancing relevance and clinician engagement

Built the national marketing strategy across a broad women’s health and specialty portfolio during a period of organisational merger and market disruption. The role combined strong commercial delivery with education-led engagement, patient insight and stakeholder partnership to support appropriate adoption and access across iron deficiency, hormonal replacement therapy and migraine, alongside other chronic conditions.

· Led go-to-market strategy and execution across portfolios including women’s health (HRT, iron deficiency), cystic fibrosis, migraine, diabetes and lipid-lowering agents

· Delivered portfolio revenue >$90M within A&P budget >$6M, while driving ~15% agency cost efficiencies

· Built and sustained strong relationships with KOLs, foundations and clinical leaders, delivering national education initiatives including the exPERT Pancreatic Endocrine Insufficiency masterclass series

· Embedded patient insight into strategy through qualitative and quantitative research, advisory boards and social listening

· Developed and launched patient-centred digital and social campaigns, increasing consumer reach and engagement

· Led and mentored a team of Product Managers across six portfolios, maintaining performance and engagement through COVID-related shifts to remote HCP access.

Responsible for national market development initiatives supporting the adoption of evidence-based, person-centred obesity care across specialist and multidisciplinary settings. The role focused on building clinical capability, strengthening standards of care pathways and aligning stakeholders to improve quality, access and consistency of care.

· Developed and progressed a national roadmap to support improved obesity care, aligning policy engagement, clinical standards and patient advocacy

· Supported the establishment and governance of the National Association of Clinical Obesity Services (NACOS), which led the development of the National Framework for Clinical Obesity Services

· Contributed to consultation processes for the National Framework for Clinical Obesity Services, working with clinicians, consumer representatives and government stakeholders to strengthen system-wide quality, coordination and accountability, along with clearer standards and more equitable care pathways

· Collaborated on The Obesity Collective strategy, developed in partnership with PwC Impact Assembly, which informed the consultative process for the National Obesity Strategy 2022–2032, embedding prevention, equity and lived-experience-led change

· Established and coordinated the Obesity Policy Engagement Network (OPEN), convening clinicians, consumer advocates, researchers and government representatives to support aligned advocacy and policy action nationally and globally

· Supported the development and uptake of evidence-based, person-centred models of care, strengthening multidisciplinary capability and access to quality support.

Key responsibilities & outcomes

Led national marketing strategy and execution across oncology, urology and dermatology portfolios, including cancer diagnostics and treatment pathways. Drove market share growth through strong KOL engagement, multi-channel strategy and aligned commercial execution in specialist-led environments.

· Delivered market share growth from 12% to 14.5% in a flat market through targeted clinician engagement, positioning and execution strategies

· Managed full P&L and partner contracts, ensuring strong commercial performance and disciplined budget management

· Built and led strategic KOL partnerships across urology–oncology networks, including PCFA and ANZUP, strengthening clinical engagement and supporting product adoption

· Led development and execution of a multi-channel engagement strategy, including digital platforms, webinars and AR tools, increasing clinician reach and engagement

· Developed and launched a patient support app and expanded nurse-led support programs, strengthening treatment navigation and supporting sustained utilisation

· Led launch planning and implementation of Cxbladder genomic biomarker testing, aligning market access, logistics and stakeholder engagement to support successful market entry

· Convened national urology and oncology forums, including the annual Tolmar Uro-Oncology Symposium, strengthening education, engagement and consistency of clinical practice

Key responsibilities & outcomes

This role focused on commercial strategy and portfolio performance across ophthalmology, immunisation and selected specialty therapeutic areas during a period of significant PBS reform and market change. The role focused on improving early diagnosis, strengthening specialist care pathways and supporting clinician and community capability through evidence-based engagement.

• Oversaw brand planning and execution across ophthalmology and specialty portfolios, navigating statutory price cuts and new competitor entrants

• Redesigned ophthalmology service and engagement models, improving reach and frequency while reducing field force and logistics costs by ~30%

• Developed and implemented the Targeting Glaucoma Awareness pilot in partnership with Glaucoma Australia, supporting earlier detection and reducing avoidable vision loss

• Worked with clinicians and consumer organisations to strengthen early-diagnosis pathways through evidence-aligned education initiatives

• Designed insight-informed education and support programs to enhance shared decision-making and patient understanding

• Collaborated across teams - medical, market access, policy and community partners, to align evidence, lived-experience insight and communication strategies

• Supported development of a childhood vaccination app (Vaximate) to improve access to timely immunisation information

• Partnered closely with sales teams to align strategy with field execution, strengthening customer engagement and supporting portfolio growth

Provide governance oversight for a rights-based disability services organisation supporting approximately 600 people across six service hubs. The organisation delivers complex, regulated supports, working closely with participants, families, carers and frontline workforces within a nationally governed quality and safeguarding framework.

The role focuses on strengthening service quality, safeguarding systems, clinical governance, risk management and accountability, while ensuring consumer voice and lived-experience perspectives are embedded in organisational decision-making. This governance experience grounds my work in the realities of service delivery, workforce pressures, regulatory compliance and the practical challenges of implementing quality and safety frameworks at scale.

• Chair of the Quality, Safeguarding & Governance Committee, overseeing safeguarding frameworks, clinical governance alignment, incident management, risk controls and continuous improvement

• Champion inclusive, rights-based governance, embedding lived-experience perspectives, codesign approaches and culturally safe practice across decision-making

• Support the CEO and executive team to uplift service quality and workforce capability, reinforcing values-aligned and person-centred practice consistent with NDIS Practice Standards

Established Mambourin’s Lived Experience Advisory Group (LEAG) and initiated a Carer’s Circle, ensuring participant, family and carer voices inform strategy, policy and quality outcomes.

• Guided the introduction of nurse-led quality roles to strengthen clinical oversight, safeguarding responsiveness and organisational learning

• Promote transparent accountability, reflective practice and values-driven leadership, contributing to safer service environments and improved participant experience.